Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLACE: Regorafenib + Pembrolizumab vs TACE/TARE in Intermediate-stage HCC (Beyond Up-to-7)
jRCT2051240126Phase 3Suspended
- Sponsor
- Translational Research In Oncology
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of regorafenib and pembrolizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Translational Research In Oncology. Primary endpoint: Progression-free survival (PFS) by mRECIST (Investigator-assessed). Started Sep 2024; status: suspended.
02
Drugs
regorafenibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2051240126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240126.